March 2023 - BioMedWire (BMW)

FridayMar 24, 2023 12:46 pm

Lighting Up Malignant Tissues Could Boost Precision of Surgical Removal

In most cases, the early discovery of cancer is directly tied to a patient’s chances of surviving the condition. Completely curing cancer may not be an option, but clinicians have several tools that allow them to kill off the majority of cancer cells and prevent them from spreading to healthy tissue. Surgery is usually considered when a tumor is present in only one part of the body and can be surgically removed in all its entirety. This approach to cancer treatment tends to be seen as “curative” because it seeks to completely remove cancer cells from the body. In many…

FridayMar 24, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Hits Key Milestone in Global GBM Clinical Trial with the Enrollment of First Patient in Spain

CNS recently enrolled the first patient in Spain in its ongoing global trial evaluating its lead drug candidate, Berubicin, for the treatment of recurrent glioblastoma multiforme (“GBM”) This milestone is the culmination of years of meticulous planning and execution The enrollment of this first patient follows the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain and Switzerland CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma and neuro-oncology, just enrolled its first patient in Spain, marking…

ThursdayMar 23, 2023 12:41 pm

New Approach Could Boost Current Asthma Medication Efficacy

Asthma is a respiratory condition that affects 26.5 million Americans and around 300 million people worldwide. It is characterized by chronic inflammation in the lung airways that results in chest tightness, wheezing, shortness of breath or coughing. This tightening usually occurs when the involuntary muscles in the lung airways contract due to exposure to allergens, fumes, second-hand smoke or toxins. Treatment typically involves avoiding allergens and using remedies such as bronchodilators and anti-inflammatory agents. More specifically, drugs that can stimulate the β2-adrenergic receptors (β2AR) are instrumental in relaxing the lung airway muscles and promoting normal lung function. However, as with…

WednesdayMar 22, 2023 1:55 pm

Hair Loss in Women May Indicate Other Conditions

Pattern hair loss is a common condition that affects men as well as millions of women. Losing hair can be caused by many things, ranging from stressful events to changes in an individual’s hormones. The most common cause of hair loss is a hereditary condition that causes the hair to thin at the top of an individual’s scalp. The condition may also indicate the presence of health issues, said Dr. Valerie Callender. Callender is a dermatology professor at the College of Medicine, Howard University and an expert at the American Academy of Dermatology. In a recent academy news release, Callender…

TuesdayMar 21, 2023 1:43 pm

Researchers ID Substance That Could Make Autoimmune Disease Treatment Possible

Japanese researchers have discovered a chemical compound that could finally make the treatment of autoimmune disorders such as multiple sclerosis and rheumatoid arthritis possible. Autoimmune diseases occur when the immune system cannot differentiate between the body’s own cells and foreign invading cells, resulting in more than 80 diseases that damage various parts of the body. Common symptoms of autoimmune conditions include joint pain and swelling, swollen glands, skin problems, fatigue and recurring fever. There is currently no cure for autoimmune diseases, but physicians can deploy a variety of treatments to reduce symptoms and mitigate damage to organs. However, the recent…

TuesdayMar 21, 2023 9:00 am

India Globalization Capital Inc. (NYSE American: IGC) Reports Triple-Digit Revenue Growth, Phase 2 Study Highlights in Q3 2023 Report

Net revenue increased 133% to $332,000 in the three months ended Dec. 31, 2022, the company reports Corporate highlights included expanded trial sites, enrollment for phase 2 IGC-AD1 study Commencement of study marks milestone in IGC’s progress toward gaining FDA approval for proprietary treatment In a fragile economic environment, the third-quarter 2023 financial results reported by India Globalization Capital (NYSE American: IGC) are particularly remarkable. The company, which is pursuing effective treatment for Alzheimer’s patients suffering with agitation and other neuropsychiatric symptoms, released a report showing an increase in net revenue of 133% for the three-month period ending Dec. 31,…

MondayMar 20, 2023 1:20 pm

Normalizing Blood Vessels in Tumors Could Improve Brain Cancer Immunotherapy

Around 700,000 Americans are estimated to be living with a primary brain tumor. The deadly condition has an incredibly high fatality rate, and it significantly disrupts the quality of life of brain cancer patients and their families. Although tumors can’t be completely cured, early detection can allow doctors to deploy treatments such as radiotherapy and chemotherapy to kill off cancer cells and reduce the size of the tumor. Even so, researchers are constantly searching for novel treatment options that are capable of treating tumors more effectively and with fewer side effects on the patient. Investigators from Massachusetts General Hospital recently…

MondayMar 20, 2023 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults

New data show rising burden of most cardiovascular risk factors among young adults aged 20 to 44 in the U.S. Findings are “extremely concerning” as expert notes “we’re witnessing a smoldering public health crisis” HeartBeam has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere A recent study shows that risk factors for cardiovascular (“CV”) disease are rising among young adults (https://ibn.fm/jvjFN). Studies like this that provide critical information regarding CV disease highlight the ongoing urgency of HeartBeam’s efforts. HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram…

FridayMar 17, 2023 11:02 am

Japan to Categorize COVID-19 as Common Infectious Illness

The Japanese government recently announced that the coronavirus will be categorized as a common infectious disease on May 8, 2023. As a result, patients diagnosed with the communicable disease will have to cover medical expenses on their own. In the wake of the coronavirus pandemic in 2020, Japan’s government instituted a special response that limited the number of medical institutions that could handle COVID-19 patients. The upcoming reclassification will classify the coronavirus as a class 5 disease similar to conditions such as seasonal influenza. At the moment, Japan currently classifies COVID-19 as part of a special category that is equal…

FridayMar 17, 2023 9:45 am

Progressive Care Inc. (RXMD) Is ‘One to Watch’

Progressive Care reported a 4% year-over-year revenue increase to approximately $10.1 million for the quarter ended September 30, 2022 The company’s prescription revenue increased 16% year-over-year to almost $9.4 million during that same period In 2022, Progressive Care received nearly $6 million from a strategic investment transaction with NextPlat Corporation The company launched its ClearMetrX platform for 340B third-party administration in 2022 Progressive Care will partner with MedAvail in2023 to provide prescription dispensing kiosks Progressive Care (OTCQB: RXMD) is a health services organization based in Florida that offers personalized healthcare services and technology that supports the managed healthcare industry. Through…